AvalehtABBV34 • BVMF
add
Abbvie Inc BDR
Viimane sulgemishind
62,90 R$
Tänane vahemik
62,90 R$ - 63,90 R$
Aasta vahemik
54,36 R$ - 79,10 R$
Turuväärtus
322,03 mld USD
Keskmine maht
5,63 tuh
Uudised
Finantsandmed
Kasumiaruanne
Käive
Puhastulu
(USD) | märts 2025info | Y/Y muutus |
---|---|---|
Käive | 13,34 mld | 8,39% |
Põhitegevusega seonduv kulu | 5,28 mld | 8,44% |
Puhastulu | 1,29 mld | −6,06% |
Puhaskasumimarginaal | 9,64 | −13,31% |
Puhaskasum aktsia kohta | 2,46 | 6,49% |
EBITDA | 6,10 mld | 11,89% |
Tõhus maksumäär | 22,40% | — |
Bilansiaruanne
Kogu vara
Kõik kohustused
(USD) | märts 2025info | Y/Y muutus |
---|---|---|
Sularaha ja lühiajalised investeeringud | 5,18 mld | −71,35% |
Kogu vara | 136,16 mld | −8,54% |
Kõik kohustused | 134,70 mld | −4,35% |
Kogu omakapital | 1,46 mld | — |
Emiteeritud aktsiate arv | 1,77 mld | — |
Hinna ja väärtuse suhe P/B | 78,62 | — |
Varade tasuvus | 7,48% | — |
Kapitali tasuvus | 14,21% | — |
Rahavoog
Raha ja raha ekvivalentide muutus
(USD) | märts 2025info | Y/Y muutus |
---|---|---|
Puhastulu | 1,29 mld | −6,06% |
Põhitegevuse rahakäive | 1,64 mld | −59,53% |
Investeeringute raha | −735,00 mln | 92,33% |
Finantseerimise raha | −1,26 mld | −111,63% |
Raha ja raha ekvivalentide muutus | −349,00 mln | −106,64% |
Tasuta rahavoog | 1,12 mld | −73,12% |
Teave
AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. Its major products are: Humira, approved to treat autoimmune diseases including rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis and administered via injection; Skyrizi, an interleukin-23 inhibitor also used to treat autoimmune diseases; Rinvoq, used to treat arthritis; and Botox. Its other major products include Imbruvica to treat cancer, Vraylar to treat schizophrenia and bipolar disorder, Venclexta to treat leukemia and lymphoma, Mavyret to treat Hepatitis C, and Epkinly, a blood-cancer therapy developed in partnership with Genmab. The company is also committed to product development for other treatments of cancer, neurologic diseases, eye care, and cystic fibrosis. The company's pipeline also includes drug candidates for Parkinson's disease including Vyalev and tavapadon.
The company is ranked sixth on the list of largest biomedical companies by revenue. It is ranked 77th on the Fortune 500 and 108th on the Forbes Global 2000. Wikipedia
Asutatud
10. apr 2012
Veebisait
Töötajate arv
55 000